GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
- With the addition of the time-based analysis, the company expects topline results by the end of Q2 2024.
- Third Quarter 2023 Financial Results:
Cash position: As of September 30, 2023, GlycoMimetics had cash and cash equivalents of $49.4 million as compared to $47.9 million as of December 31, 2022. - A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.